JP2022523047A - Cd31競合剤およびその使用 - Google Patents

Cd31競合剤およびその使用 Download PDF

Info

Publication number
JP2022523047A
JP2022523047A JP2021543183A JP2021543183A JP2022523047A JP 2022523047 A JP2022523047 A JP 2022523047A JP 2021543183 A JP2021543183 A JP 2021543183A JP 2021543183 A JP2021543183 A JP 2021543183A JP 2022523047 A JP2022523047 A JP 2022523047A
Authority
JP
Japan
Prior art keywords
seq
antibody
human
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523047A5 (cg-RX-API-DMAC7.html
Inventor
ブルサック,ローレンス
ゲレイロ,セルヘ
トゥロルジュ,ダミアン
Original Assignee
エンセファ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンセファ filed Critical エンセファ
Publication of JP2022523047A publication Critical patent/JP2022523047A/ja
Publication of JP2022523047A5 publication Critical patent/JP2022523047A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021543183A 2019-01-23 2020-01-23 Cd31競合剤およびその使用 Pending JP2022523047A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305086 2019-01-23
EP19305086.1 2019-01-23
PCT/EP2020/051667 WO2020152290A1 (en) 2019-01-23 2020-01-23 Cd31 competitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022523047A true JP2022523047A (ja) 2022-04-21
JP2022523047A5 JP2022523047A5 (cg-RX-API-DMAC7.html) 2023-02-01

Family

ID=65409014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543183A Pending JP2022523047A (ja) 2019-01-23 2020-01-23 Cd31競合剤およびその使用

Country Status (13)

Country Link
US (1) US20220089765A1 (cg-RX-API-DMAC7.html)
EP (1) EP3914616A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523047A (cg-RX-API-DMAC7.html)
KR (1) KR20210119448A (cg-RX-API-DMAC7.html)
CN (1) CN113614107A (cg-RX-API-DMAC7.html)
AU (1) AU2020211728A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014574A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127520A1 (cg-RX-API-DMAC7.html)
IL (1) IL284962A (cg-RX-API-DMAC7.html)
MX (1) MX2021008672A (cg-RX-API-DMAC7.html)
SG (1) SG11202107941TA (cg-RX-API-DMAC7.html)
WO (1) WO2020152290A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
CN117567594B (zh) * 2023-11-30 2025-02-07 北京博奥森生物技术有限公司 一种模拟cd31线性分子抗原性的分支多肽制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509837A (ja) * 2010-12-30 2014-04-24 武田薬品工業株式会社 抗cd38抗体
JP2018501297A (ja) * 2014-11-04 2018-01-18 グレンマーク ファーマシューティカルズ, エセ.アー. Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
WO2018224683A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN101287764B (zh) * 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509837A (ja) * 2010-12-30 2014-04-24 武田薬品工業株式会社 抗cd38抗体
JP2018501297A (ja) * 2014-11-04 2018-01-18 グレンマーク ファーマシューティカルズ, エセ.アー. Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
WO2018224683A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. FRASCA, ET AL., BLOOD, vol. 107, no. 6, JPN6023052547, 2006, pages 2392 - 2399, ISSN: 0005395191 *

Also Published As

Publication number Publication date
IL284962A (en) 2021-09-30
MX2021008672A (es) 2021-11-03
WO2020152290A1 (en) 2020-07-30
US20220089765A1 (en) 2022-03-24
SG11202107941TA (en) 2021-08-30
AU2020211728A1 (en) 2021-08-12
CA3127520A1 (en) 2020-07-30
BR112021014574A2 (pt) 2021-10-05
KR20210119448A (ko) 2021-10-05
EP3914616A1 (en) 2021-12-01
ZA202105154B (en) 2023-01-25
CN113614107A (zh) 2021-11-05

Similar Documents

Publication Publication Date Title
US12258410B2 (en) Anti-SIRPα antibodies and methods of use thereof
TW202525859A (zh) 全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用
TWI745670B (zh) 抗cd27抗體、其抗原結合片段及其醫藥用途
JP2021529520A (ja) 抗sirp−ベータ1抗体及びその使用方法
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2023541627A (ja) Il1rapに結合する抗体及びその使用
JP2024501539A (ja) NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ
JP7627258B2 (ja) 抗bcma抗体、その抗原結合断片、及びそれらの医療用途
JP2023528535A (ja) セリン413においてリン酸化されたタウを標的化する高親和性抗体
CN112424357B (zh) 与硫酸软骨素蛋白聚糖5结合的抗体
JP2022502024A (ja) 抗ヒトcd45rc抗体及びその使用
TWI714895B (zh) 抗csf-1r抗體、其抗原結合片段及其醫藥用途
CN112512638A (zh) 抗siglec-7抗体及其使用方法
TW201904999A (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
US20220089765A1 (en) Cd31 competitors and uses thereof
JP2024505987A (ja) 抗tnfr2抗体およびその使用
EP4108683A1 (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
WO2025120583A2 (en) CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
TW202221038A (zh) 抗trop-2抗體、其抗原結合片段或其突變體、及其醫藥用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
CN121652273A (zh) Cll-1抗体及其应用
KR20260005221A (ko) Vh4-34 항원 결합 분자
HK40047611B (en) Antibody binding to chondroitin sulfate proteoglycan-5
HK40047611A (en) Antibody binding to chondroitin sulfate proteoglycan-5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240820